Filing Details
- Accession Number:
- 0001209191-11-052774
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-10-26 18:31:58
- Reporting Period:
- 2011-10-26
- Filing Date:
- 2011-10-26
- Accepted Time:
- 2011-10-26 18:31:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 353569 | Quidel Corp | QDEL | In Vitro & In Vivo Diagnostic Substances (2835) | 942573850 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219503 | Mark Pulido | P.o. Box 1334 Rancho Santa Fe CA 92067 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-10-26 | 3,730 | $5.08 | 18,660 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2011-10-26 | 10,000 | $5.45 | 28,660 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-10-26 | 13,730 | $17.09 | 14,930 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Options | Disposition | 2011-10-26 | 3,730 | $0.00 | 3,730 | $5.08 |
| Common Stock | Non-Qualified Stock Options | Disposition | 2011-10-26 | 10,000 | $0.00 | 10,000 | $5.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2006-08-21 | 2012-08-21 | No | 4 | M | Direct |
| 0 | 2004-05-21 | 2013-05-21 | No | 4 | M | Direct |
Footnotes
- The weighted average purchase price for these transactions was $17.0878 per share, with a range of $17.00 to $17.38 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.
Billionaire Hedge Funds
